CARTALAX: WHAT IS IT? · Peptide Index

CARTALAX: WHAT IS IT?

🧬 CARTALAX: WHAT IS IT?

Cartalax is the "joint / cartilage" name on most bioregulator lists. People talk about it for knees, cartilage, and aging joints. The published research is still mostly cells in a dish from one research group. Here's the simple version.

WHAT IT IS

Cartalax is a short lab-made peptide of three amino acids: alanine, glutamic acid, and aspartic acid (written Ala-Glu-Asp, or AED). In older papers from the same group it also shows up as T-31. It comes from the Khavinson bioregulator program in St. Petersburg, Russia — the same lineage as Epitalon, Cortagen, and Livagen. It was designed as a small synthetic stand-in for ideas behind a cartilage-and-bone tissue extract (often discussed alongside a complex called Sigumir).

WHAT PEOPLE USE IT FOR

• Joint and cartilage support talk in the longevity community

• Connective-tissue and "aging chondrocyte" conversations

• Stacking talk with other short Khavinson peptides

WHAT THE RESEARCH ACTUALLY SHOWS

• Human stem cells in a dish (2023): AED raised markers that cartilage-forming cells use to build matrix — including SOX9, aggrecan, type II collagen, and COMP — in aged mesenchymal stem cells (Linkova / Khavinson group).

• Aging cartilage cells in a dish (2023): AED helped normalize a senescence-style profile (raised p16, p21, p53, and some inflammatory signals; lowered Sirt1) in aged chondrocytes from the same research lineage.

• Animals: indexed living-animal work is thin. A 2007 rat bone-density study compared a cartilage extract with "T-31" (later identified as AED); the extract did better. A developer's 2023 review mentions osteoarthritis models and older patients taking it by mouth, but those joint studies are not sitting as clear, independently indexed trials you can pull up the way you would a big RCT.

• Humans: no controlled, registered clinical trial of Cartalax/AED for joint disease was found on ClinicalTrials.gov.

Evidence level: Very Early. Cell studies (and limited related animal work), nearly all from one research lineage, with no independent replication and no solid human outcome data for cartilage repair.

COMMON QUESTIONS

Is Cartalax a proven joint medicine? No. It is not approved in the US for osteoarthritis or any joint condition, and it has not been shown in a clear controlled human trial to rebuild cartilage.

Is it the same as BPC-157 or TB-500? No. Those are different peptides with different research stories. Cartalax is the short AED "cartilage" bioregulator from the Khavinson list.

Does a change in lab cells mean it fixes knees? No. Gene and marker shifts in a dish are a starting point for research, not proof that a real joint gets healthier.

EASY WAY TO REMEMBER IT

Cartalax = the AED "cartilage" bioregulator, studied mostly in cells, with no solid human joint trials yet.

BOTTOM LINE

Cartalax is a clearly defined short peptide with a small preclinical literature aimed at cartilage and bone ideas. It is an interesting research name, not a proven joint treatment. Anyone with real joint pain should stick with care that has real evidence behind it.

We'll keep breaking these down one name at a time in plain English.

0 comments

CARTALAX: WHAT IS IT?